Note that the content is AI-generated and might contain mistakes. Generation might take some time.
If AI keeps you waiting, feel free to play the mini-game below in the meantime!
September 18, 2025
To
The Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
To
The Department of Corporate Services,
BSE Limited
25th floor, P. J. Towers,
Dalal Street, Mumbai – 400 001
Scrip Symbol: COHANCE
Scrip Code – 543064
Dear Sir/Madam,
Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 – clarification on reported news in electronic media.
This is in reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015
(“SEBI
Listing
Regulations”)
regarding
reported
news
in
electronic
media,
https://x.com/CNBCTV18News/status/1968556128444531120 & https://youtu.be/dwiwfb5UaZE?si=ZL1YWgM0VU1Qeo-9,
amongst others, on September 18, 2025, with respect to disclosure to the stock exchanges made by the Company on
August 13, 2025 in relation to USFDA inspection.
In this connection, we would like to inform that the Company vide intimation dated August 13, 2025, made a
disclosure regarding completion of inspection by the USFDA at our Finished Dosage Formulations Manufacturing
Facility (FDF Unit-I) located in Nacharam, Hyderabad, where we have received Form 483 with 6 (six) observations.
In view of the reported news in the aforesaid electronic media analysing the Form 483 observations, we wish to
clarify that the Company has submitted a comprehensive Corrective and Preventive Action (CAPA) plan within the
stipulated timeframe. We are actively engaging with the USFDA and remain committed to ensuring the highest
standards of quality and compliance across all our manufacturing facilities.
We would like to highlight that in FY2025, US revenues from this facility contributed less than 2% of consolidated
revenues, with related EBITDA contribution below 1%, indicating no material impact.
We would like to inform that we remain committed to maintaining the highest standards of quality and regulatory
compliance in all our operations and will continue to ensure the manufacture and supply of high-quality
pharmaceutical products for global markets.
This is for your information and record.
Thanking you.
Yours faithfully,
For Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)
Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal
